A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread


Study Number
844420
Phase
III
Age Group
Adult
Purpose

The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread.

Full Title

A Phase 3, Open-label, Randomized, Non-Inferiority Trial of Subcutaneous (SC) versus Intravenous (IV) Nivolumab in Advanced, or Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Who Have Received Prior Anti-Angiogenic Therapy

ClinicalTrials.Gov ID
NCT04810078

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.